Abstract
Providing high quality evidence is considered extremely challenging in rare diseases, inter alia due to substantially low patient numbers and high disease burden. However, high-quality comparative evidence is essential for the benefit assessment and price negotiations in Germany. This analysis aims to identify whether there is an evident correlation of population size and evidence quality and to subsequently analyze the potential impact for orphan drugs on price negotiation outcomes in Germany – despite the currently existing privileges.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
